Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Urology|October 4, 2021
Parenchymal Volume Replacement by Renal Cell Carcinoma Prior to Intervention: Predictive Factors and Functional ImplicationsDiego Aguilar Palacios, Rebecca A Campbell, Yosuke Yasuda, et al.
Urology|June 22, 2024
Clinical Upstaging After Neoadjuvant Chemotherapy Impacting Eligibility for Vaginal-sparing Cystectomy: Identifying Bladder Cancer Patients Who May Benefit From Interim ImagingWilliam J Liu, Rebecca A Campbell, Patrick D Michael, et al.
European Urology Open Science|May 16, 2022
Split Renal Function Is Fundamentally Important for Predicting Functional Recovery After Radical NephrectomyNityam Rathi, Yosuke Yasuda, Diego Aguilar Palacios, et al.
Urology|September 11, 2016
Functional Implications of Renal Tumor Enucleation Relative to Standard Partial NephrectomyRobert H Blackwell, Belinda Li, Zachary Kozel, et al.
Asian Journal of Surgery|September 6, 2023
Trimethylamine-N-oxide (TMAO) and predicted risk of cardiovascular events after partial nephrectomyXiangpeng Zou, Longbin Xiong, Zhixing Guo, et al.
The American Journal of Surgical Pathology|June 26, 2023
Renal Neoplasia Occurring in Patients With PTEN Hamartoma Tumor Syndrome : Clinicopathologic Study of 12 Renal Cell Carcinomas From 9 Patients and Association With Intrarenal "Lipomas"Diana Kozman, Chia-Sui Kao, Jane K Nguyen, et al.
Urology|April 11, 2022
Pathologic Findings and Management of Renal Mass in Horseshoe KidneysYosuke Yasuda, J J Zhang, Worapat Attawettayanon, et al.
European Urology Open Science|February 6, 2023
Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell CarcinomaHajime Tanaka, Shohei Fukuda, Koichiro Kimura, et al.
Urology|February 5, 2013
Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trialJerome F O'Hara, Ramatia Mahboobi, Steven M Novak, et al.
BJU International|March 25, 2016
Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinomaZachary Hamilton, Hak J Lee, Juan Jimenez, et al.
Pageof 23